Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
177Lu-JH04 in FAP-Positive Tumors
NCT06636617Phase 1Recruiting
- Sponsor
- The First Hospital of Fujian Medical University
- Start
- Aug 2024
- Primary completion
- Aug 2025
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates
- Countries
- 1
01
Overview
Phase 1, open-label trial of 177Lu-JH04 in solid tumor (3 cohorts), sponsored by The First Hospital of Fujian Medical University. Primary endpoint: Toxic and side effect. Started Aug 2024; status: recruiting.
02
Drugs
177Lu-JH04
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06636617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06636617.